Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus prolonged infusion of ceftolozane-tazobactam in ventilator-associated pneumonia due to Pseudomonas aeruginosa
2018-000059-42Phase 3Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ceftolozane + tazobactam in ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP) and Pseudomonal infection (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Time above 5 times MIC over the dosing interval. Started Apr 2018; status: active.
02
Drugs
ceftolozane + tazobactam
03
Conditions
ventilator-associated pneumonia (VAP)hospital-acquired pneumonia (HAP)Pseudomonal infection
Beyond the preview
Go deeper on 2018-000059-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000059-42.